ライフサイエンスコーパス: emollient

1 re not robustly related to the pH of applied emollient.

2 pared with another intervention or a vehicle/emollient.

3 h that had a potential relationship with the emollient.

4 ents in the control arm were asked to use no emollients.

5 example, fragrances and other ingredients in emollients.

6 or tacrolimus ointment than for steroids and emollients.

7 without the requirement to constantly apply emollients.

8 ty of various topical agents, and the use of emollients.

9 All children and parents received emollient and patient education about AD and basic skin

10 otype included transepidermal water loss and emollient and retinoid use.

11 evaluating infant feeding and the impact of emollient and steroid use in infants with dry skin for t

12 ars was similar between groups (92/609 [15%] emollients and 87/632 [14%] controls, adjusted relative

13 Topically applied formulations (e.g., emollients and moisturizers) may influence the optical p

14 by wearing impermeable gloves) and applying emollients and potent topical glucocorticoids.

15 s randomized clinical trial found that daily emollient application beginning before age 9 weeks in a

16 ndomized to 1 of 2 groups: a daily full-body emollient application daily moisturizer group starting b

17 Daily emollient application during the first year of life does

18 rth and randomised 1:1 to either twice-daily emollient application for the first 8 weeks of life (int

19 Interventions were mainly emollients, applied for the first 3-12 months.

20 Several studies have evaluated prophylactic emollients as a preventive strategy against atopic derma

21 ess of these approaches, such as the type of emollient chosen for the intervention, the role of manag

22 ally higher in children with frequent use of emollients compared to uncommon users, reaching statisti

23 show that applying a thin layer of glycerine emollient containing nanoparticles of either calcium car

24 ionate, clobetasol propionate, and a vehicle/emollient control.

25 Patients cited topical emollients, corticosteroids, and salicylic acid along wi

26 stamines, topical corticosteroids, and thick emollient creams, rendering their eruption tolerable for

27 re randomly assigned (1:1) to application of emollient daily (either Diprobase cream or DoubleBase ge

28 emollient group, which were advised to apply emollient (Doublebase Gel or Diprobase Cream) to their c

29 dvice given in the BEEP trial to apply daily emollient during infancy for eczema prevention in high-r

30 We found no evidence that daily emollient during the first year of life prevents eczema

31 Regular emollients during infancy probably do not prevent eczema

32 vention trial evaluated the effects of daily emollients during the first year of life on atopic derma

33 centre, randomized-controlled trial of daily emollient for the first year of life for primary prevent

34 The effectiveness of emollients for preventing atopic dermatitis/eczema is co

35 8 infants with outcome data collected in the emollient group and 150 (25%) of 612 infants in the cont

36 months was reported for 188/608 (31%) in the emollient group and 178/631 (28%) in the control group (

37 , and Nov 18, 2016; 693 were assigned to the emollient group and 701 to the control group.

38 Although more parents in the emollient group reported food reactions in the previous

39 more frequent moisturizer application in the emollient group through to 5 years.

40 er child in year 1 was 0.23 (SD 0.68) in the emollient group versus 0.15 (0.46) in the control group;

41 Adherence in the emollient group was 88% (466 of 532) at 3 months, 82% (4

42 mollient plus standard skin-care advice (693 emollient group) or standard skin-care advice alone (701

43 e first year plus standard skin-care advice (emollient group) or standard skin-care advice only (cont

44 djusted incremental costs were lower for the emollient group, -pound 106.89 (95% CI -354.66, 140.88)

45 tal QALYs were very slightly improved in the emollient group, 0.0010 (95% CI -0.0069, 0.0089).

46 of atopic disease were randomised 1:1 to the emollient group, which were advised to apply emollient (

47 measures such as the application of topical emollients have shown mixed results in the prevention of

48 Topical emollients improved neonatal skin condition, but were as

49 We tested whether daily use of emollient in the first year could prevent eczema in high

50 sise the evidence for topical application of emollients in the prevention of invasive infection and m

51 were small changes in prescribing over time; emollients increased (prescribed to 48.5% of people with

52 were small changes in prescribing over time; emollients increased and topical corticosteroids decreas

53 The prophylactic application of emollients initiated in early infancy may prevent AD, es

54 , which assessed the effects of prophylactic emollients initiated within the first 6 weeks of life on

55 Few studies have evaluated emollient intervention for primary AD prevention in infa

56 < .001), and (4) development of AD with the emollient intervention.

57 Emollients make up the basis of the therapy.

58 We hypothesize that emollients may delay rather than prevent AD.

59 Topical emollients might improve skin integrity and barrier func

60 ffect of prophylactic application of topical emollient (ointments, creams, or oils) on the incidence

61 ctive effect was found with the use of daily emollient on the cumulative incidence of atopic dermatit

62 conceivable to design resveratrol-containing emollient or patch, as well as sunscreen and skin-care p

63 topic disease were randomized (1:1) to daily emollient plus standard skin-care advice (693 emollient

64 ial data do not provide strong evidence that emollients prevent invasive infection or death in preter

65 There were no emollient-related adverse events and no differences in a

66 cidence of infection in infants treated with emollient (relative risk 1.20, 95% CI 1.01-1.42), but no

67 here was significant benefit of prophylactic emollients (RR 0.75, 95% CI 0.62-1.11) in the high-risk

68 weeks of life (intervention group), using an emollient specifically formulated for very dry, AD-prone

69 dence on efficacy and safety of prophylactic emollients started during the first 6 weeks of infancy f

70 s explained by increased use of the specific emollients that are used to treat pruritic and inflamed

71 ntion arm were instructed to apply full-body emollient therapy at least once per day starting within

72 nd continuum of care delivery strategies for emollient therapy for newborn infants at highest risk of

73 The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe

74 If confirmed in larger trials, emollient therapy from birth would be a simple and low-c

75 , potentially extending the applicability of emollient therapy in very low-birth-weight (VLBW) infant

76 In infants given emollients, there was no significant reduction on the de

77 to ascertain whether topical application of emollients to enhance skin barrier function would preven

78 a, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn.

79 Emollient use and atopic dermatitis were associated with

80 orkers or participants and by measurement of emollient use based on caregiver responses and not actua

81 We investigated if daily emollient use from birth to 2 months reduced AD incidenc

82 d that early initiation of daily specialized emollient use until 2 months reduces the incidence of AD

83 To evaluate the association between emollient use, atopic dermatitis and FLG mutations, resp

84 weeks or a control group that refrained from emollient use.

85 a vapor-permeable membrane (Gore-Tex) or an emollient (Vaseline), applied after acute barrier disrup

86 formation about atopic dermatitis and use of emollients was obtained from questionnaires completed by

87 95% CI 0.43, 0.81) in studies (n = 6) where emollients were used continuously to the point of AD ass

88 Emollient (with either basic pH 8.5 or pH 5.5) was appli